Skip to main content
Premium Trial:

Request an Annual Quote

People in the News: Tim Cooley, Kevin Krenzke, Ardy Arianpour

Premium

MolecularHealth has added two new members to its US executive team: Tim Cooley and Kevin Krenzke.

Cooley will be senior VP of IT at MolecularHealth. He previously spent 15 years at Eli Lilly, where he held various positions, including director of IT. Krenzke will be senior VP of finance at MolecularHelath. He joins the firm after holding leaderships roles at McKesson Specialty Health and US Oncology.

The new additions to the MolecularHealth team come as the company is readying to launch TreatmentMAP, a cancer treatment decision support tool, in the first quarter.


Ardy Arianpour has joined Pathway Genomics as chief strategy officer, the company said this week.
Arianpour most recently was senior VP of business development at Ambry Genetics, and during his 13-year career in the biotech sector he also has worked in senior sales and business development roles at Clinical Data, Cogenics, and Eurogentec North America. In his new post, Arianpour will lead the San Diego-based company's global strategy, strategic planning, and partnership activities.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.